Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Redirecting the cellular immune response.

U D Staerz1, M J Bevan

  • 1Basel Institute for Immunology, Switzerland.

International Reviews of Immunology
|May 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

High determinant density may explain the phenomenon of alloreactivity.

Immunology today·2014
Same author

Use of anti-receptor antibodies to focus T-cell activity.

Immunology today·2014
Same author

Thymic education.

Immunology today·2014
Same author

Antigen specific suppression of T-cell responses - the veto concept.

Immunology today·2014
Same author

An unusual case of extra bone formation.

Rheumatology (Oxford, England)·2005
Same author

The Nrarp gene encodes an ankyrin-repeat protein that is transcriptionally regulated by the notch signaling pathway.

Developmental biology·2002
Same journal

Leptin in metabolic-immune crosstalk: Mechanisms of T cell regulation and implications for autoimmune disease therapy.

International reviews of immunology·2026
Same journal

Metabolic alterations in the tumor microenvironment influence the anti-tumor immune function of CD8<sup>+</sup> T cells via epigenetic modifications.

International reviews of immunology·2026
Same journal

Macrophage markers and gene signature profiling reveals mesenchymal stem cells mediated immune modulation in Plasmodium berghei ANKA infection.

International reviews of immunology·2026
Same journal

Natural antigen landscape shaping intestinal Treg cells: Self, diet, and microbiota.

International reviews of immunology·2026
Same journal

Upregulation of ADAM10 reinforces CD8<sup>+</sup> T cells toward exhaustion in the TME.

International reviews of immunology·2026
Same journal

PTX3 promotes macrophage efferocytosis and inflammation resolution in granulomatous mastitis.

International reviews of immunology·2026
See all related articles

This study introduces hybrid antibodies that direct T cells to eliminate targeted cells, showing promise for treating viral infections and tumors. Pilot studies in animals demonstrated significantly improved survival rates in tumor models.

Area of Science:

  • Immunology
  • Biotechnology
  • Oncology

Background:

  • T lymphocytes are crucial for immune responses against infections and tumors.
  • Monoclonal antibodies offer targeted therapeutic potential.
  • Combining T cell activity with antibody targeting presents a novel therapeutic strategy.

Purpose of the Study:

  • To develop and evaluate hybrid antibodies for targeted T cell activation.
  • To assess the efficacy of this technology against viral infections and tumor cells in vitro.
  • To investigate the in vivo therapeutic potential in a preclinical tumor model.

Main Methods:

  • Construction of heteroconjugate and hybrid antibodies with dual specificity (anti-T cell receptor and anti-target antigen).
  • In vitro assessment of T cell-mediated cytotoxicity against target cells (viral-infected and tumor cells).

Related Experiment Videos

  • In vivo pilot studies using a tumor model to evaluate survival rates.

    • Main Results:

    • Hybrid antibodies successfully focused T cells to target sites in vitro.
    • Demonstrated efficacy in eliminating viral-infected cells and tumor cells in vitro.
    • In vivo experiments showed a significant increase in survival rates in treated animals compared to controls.

    Conclusions:

    • Hybrid antibodies represent a promising platform for redirecting T cell immunity.
    • This technology holds potential for treating viral diseases and cancers.
    • Further in vivo studies are warranted to explore clinical applications.